We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.

U.S. Markets open in 3 hrs 8 mins

Orexigen Therapeutics, Inc. (OREX)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
0.2229-0.1170 (-34.42%)
At close: 4:00PM EDT
Full screen
Previous Close0.3399
Open0.2449
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2200 - 0.3198
52 Week Range0.1700 - 3.1300
Volume3,735,420
Avg. Volume2,115,554
Market Cap4.21M
Beta1.60
PE Ratio (TTM)N/A
EPS (TTM)-9.6580
Earnings DateNov 1, 2017 - Nov 6, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.50
Trade prices are not sourced from all markets
  • The Wall Street Journal25 days ago

    [$$] Firm Retention Summary: Orexigen Therapeutics Inc.

    This is a summary of a request from the official committee of unsecured creditors of Orexigen Therapeutics Inc. to hire Irell & Manella LLP as counsel, filed April 27 with the U.S. Bankruptcy Court in ...

  • The Wall Street Journallast month

    [$$] Pernix, Investor Group Offer $75 Million for Orexigen

    The offer, revealed Monday in a filing in U.S. Bankruptcy Court in Wilmington, Del., is subject to higher bids at a court-supervised auction. The deal would include the world-wide rights to anti-obesity drug Contrave. to name the investor group’s acquisition vehicle, Nalpropion Pharmaceuticals Inc., as the stalking horse, or lead bidder, at the auction.

  • PR Newswirelast month

    Orexigen Therapeutics, Inc. Enters Agreement for Sale of Company

    SAN DIEGO, April 23, 2018 /PRNewswire/ -- Orexigen Therapeutics, Inc. (OREX), a biopharmaceutical company focused on the treatment of obesity, announced today that it has entered into an asset purchase agreement with Nalpropion Pharmaceuticals, Inc. to sell substantially all of the assets of the company, subject to court approval.  Under the terms of the agreement, Orexigen will sell the world-wide rights to Contrave® (naltrexone HCl / bupropion HCl extended release) /Mysimba™ (naltrexone HCl and bupropion HCl prolonged release) and certain other Orexigen assets for $75 million in cash. The deal is subject to higher and better offers.

  • The Wall Street Journal2 months ago

    [$$] Orexigen Incentive, Retention Plans Opposed by Unsecured Creditors

    Drugmaker’s sale targets are too easy to hit, creditors committee says

  • The Wall Street Journal2 months ago

    [$$] Firm Retention Summary: Orexigen Therapeutics Inc.

    This is a summary of a request from Orexigen Therapeutics Inc. to hire Morris Nichols Arsht & Tunnell LLP as Delaware bankruptcy co-counsel, filed March 23 with the U.S. Bankruptcy Court in Wilmington, ...

  • This Obesity Drugmaker Just Made a Comeback While Another Declared Bankruptcy
    Motley Fool2 months ago

    This Obesity Drugmaker Just Made a Comeback While Another Declared Bankruptcy

    It's all about the pipeline.

  • Should You Buy Orexigen Therapeutics Inc (NASDAQ:OREX) At $0.22?
    Simply Wall St.2 months ago

    Should You Buy Orexigen Therapeutics Inc (NASDAQ:OREX) At $0.22?

    Orexigen Therapeutics Inc (NASDAQ:OREX), a pharmaceuticals company based in United States, received a lot of attention from a substantial price movement on the NasdaqGS in the over the last fewRead More...

  • 30 Most Obese Countries In The World in 2018: Biggest Anti-Obesity Drug Markets
    Insider Monkey2 months ago

    30 Most Obese Countries In The World in 2018: Biggest Anti-Obesity Drug Markets

    The 30 most obese countries in the world in 2018 represent a huge (pun intended) market opportunity for weight loss drugmakers. Increasingly sedentary lifestyles and a lack of healthy eating habits among large swaths of the global population have resulted in dramatically rising obesity rates in the past few decades, particularly in urban settings. Obesity is […]

  • Biotech Stock Roundup: REGN Cuts Praluent Price, OREX to File for Bankruptcy
    Zacks3 months ago

    Biotech Stock Roundup: REGN Cuts Praluent Price, OREX to File for Bankruptcy

    The biotech sector was in focus last week with key news - Orexigen going bankrupt, Biogen acquires asset from Pfizer, Regeneron cuts Praluent price among others.

  • Orexigen Plummets on Filing of Chapter 11 of Bankruptcy Code
    Zacks3 months ago

    Orexigen Plummets on Filing of Chapter 11 of Bankruptcy Code

    Shares of Orexigen (OREX) have declined more than 75% of its value as the company announced that it is filing for bankruptcy.